Trial Profile
A Study Assessing And Characterizing Incidence Of Antiandrogen Withdrawal Syndrome (AAWS) After Enzalutamide (ENZA) In Patients With Metastatic Castration-Refractory Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.